MapLight Therapeutics stock tumbles 40% on trial results
Investing.com -- MapLight Therapeutics, Inc. (NASDAQ:MPLT) shares fell 40% Monday after the company announced topline results from its Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, with the once-daily dose failing to meet its primary endpoint.
Reported by 1 outlet — Investing.com · Stock Market. See all sources ↓
Investing.com -- MapLight Therapeutics, Inc. (NASDAQ:MPLT) shares fell 40% Monday after the company announced topline results from its Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, with the once-daily dose failing to meet its primary endpoint. The trial met its primary endpoint with the 210/3 mg twice-daily dose demonstrating a statistically significant improvement in PANSS total score compared to placebo at Week 5, with an effect size of 0.37. However, the 330/6 mg once-daily dose, which results in lower daily exposure than twice-daily dosing, demonstrated numerical improvement over placebo but did not achieve statistical significance on the primary endpoint.
Read the full report at Investing.com · Stock Market ↗
Why it matters
A world story we're tracking; its significance and source trust firm up as more outlets confirm it.
- What's the story?
- Investing.com -- MapLight Therapeutics, Inc. (NASDAQ:MPLT) shares fell 40% Monday after the company announced topline results from its Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, with the once-daily dose failing to meet its primary endpoint.
- How widely is it covered?
- 1 outlet, average source rating 6.0/10.
- When was it last updated?
- 6m ago.
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
MapLight Therapeutics stock tumbles 40% on trial results
Sources1TypeCoverageInvesting.com · Stock Market